

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 September 2022 (15.09.2022)



(10) International Publication Number
WO 2022/192536 A1

(51) International Patent Classification:

A61K 38/00 (2006.01) A61P 25/28 (2006.01)
A61K 38/17 (2006.01) C07K 14/54 (2006.01)
A61P 25/00 (2006.01)

(21) International Application Number:

PCT/US2022/019748

(22) International Filing Date:

10 March 2022 (10.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/159,919	11 March 2021 (11.03.2021)	US
63/225,846	26 July 2021 (26.07.2021)	US
63/310,839	16 February 2022 (16.02.2022)	US

(71) Applicants: **THE METHODIST HOSPITAL** [US/US];
6565 Fannin Street, MS D-200, Houston, TX 77030 (US).
COYA THERAPEUTICS, INC. [US/US]; 12645 Memorial Drive, Suite F1#305, Houston, TX 77024 (US).

(72) Inventors: **APPEL, Stanley, Hershi**; 1111 Herman Drive, #30D, Houston, TX 77004 (US). **FARIDAR, Alireza**; 1701 Herman Drive, Apt 4F, Houston, TX 77004 (US). **BERMAN, Howard**; 850 San Felipe Street, Suite 500, Houston, TX 77063 (US).

(74) Agent: **GEORGE, Nikolaos, C.** et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: METHODS AND COMPOSITIONS FOR TREATMENT OF DISEASE




FIG. 1

(57) Abstract: The present disclosure provides methods for treating diseases such as neurodegenerative and neuroinflammatory diseases, for example, Alzheimer's disease, comprising administration of a CTLA-4-containing protein, e.g., abatacept, and an IL-2 protein, e.g., aldesleukin, to a subject, either separately or in a single formulation. Also presented herein are pharmaceutical compositions comprising a CTLA-4-containing protein, e.g., abatacept, and an IL-2 protein, e.g., aldesleukin.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*